A Closer Look: Sun’s Settlement With Pfizer May Cloud Its Ability For Large Buyouts
This article was originally published in PharmAsia News
Executive Summary
With a large chunk of its cash reserves spent to settle the Protonix patent case, India’s Sun Pharma may no longer be in position to follow its inorganic growth plans.